These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18563945)

  • 1. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.
    Wettermark B; Godman B; Andersson K; Gustafsson LL; Haycox A; Bertele V
    Pharmacoeconomics; 2008; 26(7):537-50. PubMed ID: 18563945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.
    Godman B; Wettermark B; Hoffmann M; Andersson K; Haycox A; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):65-83. PubMed ID: 19371180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.
    Sermet C; Andrieu V; Godman B; Van Ganse E; Haycox A; Reynier JP
    Appl Health Econ Health Policy; 2010; 8(1):7-24. PubMed ID: 20038190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the influence of recent reforms in China: cardiovascular and cerebrovascular medicines as a case history to provide future direction.
    Zeng W; Zhen J; Feng M; Campbell SM; Finlayson AE; Godman B
    J Comp Eff Res; 2014 Jul; 3(4):371-86. PubMed ID: 25275234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
    Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
    J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insight into recent reforms and initiatives in Austria: implications for key stakeholders.
    Godman B; Bucsics A; Burkhardt T; Haycox A; Seyfried H; Wieninger P
    Expert Rev Pharmacoecon Outcomes Res; 2008 Aug; 8(4):357-71. PubMed ID: 20528343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.
    Godman B; Burkhardt T; Bucsics A; Wettermark B; Wieninger P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):475-84. PubMed ID: 19817531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forecasting drug utilization and expenditure in a metropolitan health region.
    Wettermark B; Persson ME; Wilking N; Kalin M; Korkmaz S; Hjemdahl P; Godman B; Petzold M; Gustafsson LL;
    BMC Health Serv Res; 2010 May; 10():128. PubMed ID: 20478043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of promoting access to medicines in China - problems and recommendations.
    Sun J; Hu CJ; Stuntz M; Hogerzeil H; Liu Y
    BMC Health Serv Res; 2018 Feb; 18(1):125. PubMed ID: 29458428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
    Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.
    Fraeyman J; Van Hal G; Godman B; Beutels P
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):141-51. PubMed ID: 23402454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of generic drug prices in seven European countries: a methodological analysis.
    Wouters OJ; Kanavos PG
    BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.
    Schwermann T; Greiner W; v d Schulenburg JM
    Value Health; 2003; 6 Suppl 1():S20-30. PubMed ID: 12846923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
    Godman B; Shrank W; Wettermark B; Andersen M; Bishop I; Burkhardt T; Garuolienè K; Kalaba M; Laius O; Joppi R; Sermet C; Schwabe U; Teixeira I; Tulunay FC; Wendykowska K; Zara C; Gustafsson LL
    Pharmaceuticals (Basel); 2010 Aug; 3(8):2470-2494. PubMed ID: 27713363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases.
    Goupil B; Balusson F; Naudet F; Esvan M; Bastian B; Chapron A; Frouard P
    BMJ; 2019 Nov; 367():l6015. PubMed ID: 31690553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.